Abiraterone. Cougar Biotechnology.
Abiraterone is an oral, selective, steroidal inhibitor of cytochrome P450(17alpha) being developed by Cougar Biotechnology Inc for the potential treatment of prostate cancer. Phase I clinical trials of abiraterone have been conducted and the design of phase I/II clinical trials is being finalized.
Madan
Ravi A
RA
National Cancer Institute, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, USA.
Arlen
Philip M
PM
D000726:Androgen Antagonists / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000736:Androstenes; D000737:Androstenols / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008004:Licensure; D008297:Male; D015394:Molecular Structure; D009251:NADPH-Ferrihemoprotein Reductase / Q000037:antagonists & inhibitors*; D010330:Patents as Topic; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D004791:Enzyme Inhibitors; D009251:NADPH-Ferrihemoprotein Reductase; C089740:abiraterone